EVK Stock Analysis: Evonik Industries | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 7.461m EUR | 12M Return: -4.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.5M
EPS Trend: 43.5%
Qual. Beats: 0
Rev. Trend: -90.6%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Evonik Industries AG is a German specialty chemicals company headquartered in Essen, founded in 1847. It operates globally across Asia-Pacific, Europe, the Middle East, Africa, and the Americas through three reporting segments: Advanced Technologies, Custom Solutions, and Infrastructure.
The Advanced Technologies segment supplies performance chemicals such as medical-grade polymers, hydrogen peroxide (used in semiconductor wafer cleaning and pulp/paper bleaching), specialty silicas and silanes for tires, electronics, and cosmetics, and the essential amino acids D-/L-methionine and lysine for animal feed. Evonik is one of the worlds largest producers of methionine, a key feed additive for poultry and swine, reflecting the companys deep position in life-sciences-oriented specialty chemistry rather than commodity chemicals.
The Custom Solutions segment focuses on functional additives for coatings, adhesives, sealants, polyurethane foams, and lubricants serving cosmetics, cleaning, and pharmaceutical end-markets. The Infrastructure segment supplies C4-based petrochemical intermediates, including butadiene, MTBE, butene-1, isononanol, and DINP, which feed into plastics, packaging, rubber, fuel production, and as plasticizers for the construction and automotive industries.
- Methionine oversupply pressures animal nutrition segment margins
- High European energy costs squeeze German production profitability
- Construction slowdown weakens plasticizer and coatings additives demand
| Net Income: 157.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.10 > 1.0 |
| NWC/Revenue: 13.35% < 20% (prev 14.49%; Δ -1.13% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.39b > Net Income 157.0m |
| Net Debt (4.43b) to EBITDA (1.76b): 2.51 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 22.59% > 18% (prev 24.74%; Δ -2.14% > 0.5%) |
| Asset Turnover: 70.91% > 50% (prev 74.79%; Δ -3.88% > 0%) |
| Interest Coverage Ratio: 2.59 > 6 (EBIT TTM 561.0m / Interest Expense TTM 217.0m) |
| A: 0.10 (Total Current Assets 5.43b - Total Current Liabilities 3.60b) / Total Assets 18.5b |
| B: 0.39 (Retained Earnings 7.21b / Total Assets 18.5b) |
| C: 0.03 (EBIT TTM 561.0m / Avg Total Assets 19.3b) |
| D: 0.81 (Book Value of Equity 8.23b / Total Liabilities 10.2b) |
| Altman-Z'' = 2.97 = A |
| DSRI: 1.08 (Receivables 1.82b/1.87b, Revenue 13.7b/15.1b) |
| GMI: 1.09 (GM 24.74% / 22.59%) |
| AQI: 1.01 (AQ_t 0.33 / AQ_t-1 0.33) |
| SGI: 0.91 (Revenue 13.7b / 15.1b) |
| TATA: -0.07 (NI 157.0m - CFO 1.39b) / TA 18.5b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at EUR 16.34 with a total of 783,872 shares traded. Over the past week, the price has changed by +2.06%, over one month by +6.10%, over three months by +0.09% and over the past year by -4.27%.
Current recommended Stop Loss: 15.80 (which is 3.3% or 1.3 ATR below the current price).
Evonik Industries has no consensus analysts rating.
P/E Trailing = 47.0882
P/E Forward = 19.7239
P/S = 0.5438
P/B = 0.9065
P/EG = 6.2284
Revenue TTM = 13.7b EUR
EBIT TTM = 561.0m EUR
EBITDA TTM = 1.76b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 684.0m EUR (from shortTermDebt, last quarter)
Debt = 5.02b EUR (from shortLongTermDebtTotal, last quarter) + Leases 865.0m
Net Debt = 4.43b EUR (calculated: Debt 5.02b - CCE 589.0m)
Enterprise Value = 11.9b EUR (7.46b + Debt 5.02b - CCE 589.0m)
Interest Coverage Ratio = 2.59 (Ebit TTM 561.0m / Interest Expense TTM 217.0m)
EV/FCF = 19.46x (Enterprise Value 11.9b / FCF TTM 611.0m)
FCF Yield = 5.14% (FCF TTM 611.0m / Enterprise Value 11.9b)
FCF Margin = 4.45% (FCF TTM 611.0m / Revenue TTM 13.7b)
Net Margin = 1.14% (Net Income TTM 157.0m / Revenue TTM 13.7b)
Gross Margin = 22.59% ((Revenue TTM 13.7b - Cost of Revenue TTM 10.6b) / Revenue TTM)
Gross Margin QoQ = 25.21% (prev 20.25%)
Tobins Q-Ratio = 0.64 (Enterprise Value 11.9b / Total Assets 18.5b)
Interest Expense / Debt = 4.32% (Interest Expense 217.0m / Debt 5.02b)
Taxrate = 49.11% (165.0m / 336.0m)
NOPAT = 285.5m (EBIT 561.0m * (1 - 49.11%))
Current Ratio = 1.51 (Total Current Assets 5.43b / Total Current Liabilities 3.60b)
Debt / Equity = 0.61 (Debt 5.02b / totalStockholderEquity, last quarter 8.23b)
Debt / EBITDA = 2.51 (Net Debt 4.43b / EBITDA 1.76b)
Debt / FCF = 7.25 (Net Debt 4.43b / FCF TTM 611.0m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.81% (Net Income 157.0m / Total Assets 18.5b)
RoE = 1.89% (Net Income TTM 157.0m / Total Stockholder Equity 8.30b)
RoCE = 5.15% (EBIT 561.0m / Capital Employed (Equity 8.30b + L.T.Debt 2.59b))
RoIC = 1.91% (NOPAT 285.5m / Invested Capital 15.0b)
WACC = 4.63% (E(7.46b)/V(12.5b) * Re(6.26%) + D(5.02b)/V(12.5b) * Rd(4.32%) * (1-Tc(0.49)))
Discount Rate = 6.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -3.62 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈723.8m ; Y1≈634.7m ; Y5≈512.8m
[DCF] Fair Price = 8.16 (EV 8.23b - Net Debt 4.43b = Equity 3.80b / Shares 466.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 43.47 | EPS CAGR: 12.31% | SUE: 0.71 | # QB: 0
Revenue Correlation: -90.64 | Revenue CAGR: -5.67% | SUE: -2.07 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.53 | Chg30d=+9.38% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.42 | Chg30d=-3.41% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=1.54 | Chg30d=+5.83% | Revisions=+29% | GrowthEPS=+13.3% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=1.47 | Chg30d=+2.16% | Revisions=+57% | GrowthEPS=-4.7% | GrowthRev=-0.7%
[Analyst] Revisions Ratio: +50% (up=9, down=2)